Eric T Matey, Ashley Kate Ragan, Lance J Oyen, Carolyn R Vitek, Stacy L Aoudia, Ahmed K Ragab, Kelliann C Fee-Schroeder, John L Black, Ann M Moyer, Wayne T Nicholson, Sofia Shrestha, Tammy M McAllister, Jason P Sinnwell, Stephanie S Faubion, Konstantinos N Lazaridis
PURPOSE: The Pharmacogenomics (PGx) Profile Service was a proof-of-concept project to implement PGx in patient care at Mayo Clinic. METHODS: Eighty-two healthy individuals aged 18 and older underwent genotyping of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, SLCO1B1, HLA-B*58:01, and VKORC1. A PGx pharmacist was involved in ordering, meeting with patients, interpreting, reviewing, and documenting results. RESULTS: Ninety three percent were CYP1A2 rapid metabolizers, 92% CYP3A4 normal metabolizers, and 88% CYP3A5 poor metabolizers; phenotype frequencies for CYP2C19 and CYP2D6 varied...
February 2022: Pharmacogenomics Journal